Kava in generalized anxiety disorder: Three placebo-controlled trials

International Clinical Psychopharmacology

Volumn 21, Issue 5, 2006, Pages 249-253

  Connor, Kathryn M ^a   Payne, Victoria ^b   Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Box 3812 ^*

Author keywords

Botanical treatment; Generalized anxiety disorder; Herbal treatment; Placebo

Indexed keywords

KAVA; VENLAFAXINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SAMPLE SIZE;

ANXIETY DISORDERS; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAVA; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; SEROTONIN UPTAKE INHIBITORS;

EID: 33746772805     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200609000-00001     Document Type: Article

References (23)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorder. 4th Edition. Washington, DC. American Psychiatric Publishing.
2. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M (2003). Kavakava extract LI 150 is as effective as opipramol and buspirone in generalized anxiety disorder: an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 10(Suppl 4):38-49.
3. Clouatre DL (2004). Kava kava: examining new reports of toxicity. Toxicol Lett 150:85-96.
4. Cohen J, Cohen P (1975). Applied multiple regression/correlation analysis for behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates.
5. Connor KM, Davidson JRT (2002). A placebo-controlled study of kava kava in generalized anxiety disorder. Int Clin Psychopharmacol 17:185-188.
6. Connor KM, Davidson JRT, Churchill LE (2001). Adverse effects profile of kava kava. CNS Spectrums 6:848-853.
7. Cropley M, Cave Z, Ellis J, Middleton RW (2002). Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 16:23-27.
8. Currie BJ, Clough AR (2003). Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust 178:421-422.
9. Dragull K, Yoshida WY, Tang CS (2003). Piperidine alkaloids from Piper methysticum. Phytochemistry 63:193-198.
10. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575.
11. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Kinzler E, Kromer J, Lehmann E (1991). Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks. Arzneimittelforschung 41:584-588.
13. Mathews JM, Etheridge AS, Black SR (2002). Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 30:1153-1157.
14. Moller HJ, Volz HP, Reimann IW, Stoll KD (2001). Opipramol for the treatment of generalised anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21:59-65.
15. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D (2002). Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 36:209-217.
16. Nerurkar PV, Dragull K, Tang CS (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci 79:106-111.
17. Pittler MH, Ernst E (2003). Kava extract for treating anxiety. Cochrane Database Syst Rev CD003383.
18. Russmann S, Lauterburg BH, Helbling A (2001). Kava hepatotoxicity. Ann Intern Med 135:68-69.
19. Sheehan D (1983). The anxiety disease. New York: Bantam Books.
20. Watkins LL, Connor KM, Davidson JRT (2001). Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol 15:283-286.
21. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS (2003). Kava lactones and the kava-kava controversy. Phytochemistry 64:673-679.
22. Volz HP, Kieser M (1997). Kava-kava extract WS 1490 versus placebo in anxiety disorders: a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 30:1-5.
23. Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370.